Treatment of poor prognosis epidemic Kaposi's sarcoma with doxorubicin, bleomycin, vindesine and recombinant human granulocyte-monocyte colony stimulating factor (rh GM-CSF)

European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)
P J BakkerC H Veenhof

Abstract

The efficacy and toxicity of doxorubicin, bleomycin and vindesine in epidemic Kaposi's sarcoma, and the role of rh GM-CSF in chemotherapy-induced neutropenia were evaluated in this Phase II study. Patients with progressive Kaposi's sarcoma were eligible, and were staged according to ACTG criteria. Treatment consisted of 20 mg/m2 doxorubicin, and a fixed dose of 15 mg bleomycin and 4 mg vindesine every 2 weeks. All patients continued antiretroviral medication with severe myelosuppression, patients received subcutaneous 5 micrograms/kg rh GM-CSF (Leucomax) from days 2-12. Response and toxicity were measured according to ACTG and WHO criteria. 27 patients were evaluable, 25 patients classified as having a poor prognosis. The response rate was 70% (3 CR, 16 PR), the duration of response was 18 weeks (range 8-25) and the median survival 30 weeks (range 4-63+). The cause of death was mostly opportunistic infection. 4 patients died of pulmonary Kaposi's sarcoma. The toxicity of this regimen was mainly myelosuppression and 13 patients were treated with rh GM-CSF. Complete recovery of the white blood cells occurred in seven of the 27 courses of rh GM-CSF (26%). No bacterial infections were recorded, but 5 patients (19%) developed an opp...Continue Reading

References

Apr 1, 1991·The American Journal of Medicine·P S GillM Krailo
May 1, 1990·The Journal of the South Carolina Medical Association·P H O'Brien
Jul 1, 1989·The American Journal of Medicine·P S GillA M Levine
Mar 1, 1989·Annals of Internal Medicine·J E Groopman, D T Scadden
May 1, 1988·Annals of Neurology·S M de la MonteA K Bhan
Jan 1, 1987·Chest·S M GarayR Schinella
Feb 1, 1987·Cancer·J E Groopman

❮ Previous
Next ❯

Citations

Oct 1, 1996·Hematology/oncology Clinics of North America·F C Lee, R T Mitsuyasu
Mar 1, 1996·Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [et Al.]·M J Zalla
Jan 1, 1997·Dermatologic Clinics·R R Walther

❮ Previous
Next ❯

Related Concepts

Related Feeds

HIV/AIDS-Related Malignancies

HIV/AIDS infection increases the risk of non-communicable diseases common in the aged including HIV/AIDS-related malignancies. Discover the latest research in HIV/AIDS-related malignancies.

AIDS Malignancies (ASM)

HIV infection increases the risk of non-communicable diseases common in the aged, including cardiovascular disease, neurocognitive decline, non-aids malignancies, osteoporosis, and frailty. Discover the latest research in AIDS malignancies.

Related Papers

Annals of Internal Medicine
J G SinkovicsC H Wang
Archiv Für Dermatologische Forschung
F OttolenghiR Baiocchi
© 2021 Meta ULC. All rights reserved